Regeneron First-Quarter Profit Tops Estimates on Eylea

Regeneron Pharmaceuticals Inc., maker of the eye medicine Eylea, reported first-quarter profit that topped analysts’ estimates and increased its U.S. sales forecast for the drug. The shares rose.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.